Inbakicept

Names

[ CAS No. ]:
2135939-52-3

[ Name ]:
Inbakicept

Biological Activity

[Description]:

Inbakicept (ALT-803) is an IL-15 superagonist complex, consisting of IL-15 mutant and IL-15Rα-Fc fusion. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation, IFNγ production in cells[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

[Target]

IL-15Rα


[In Vitro]

Inbakicept (0.01-1 nM；20 小时) 增强人 NK 细胞的细胞毒性并增加细胞毒性效应分子的表达[1]。 Cell Cytotoxicity Assay[1] Cell Line: Daudi, Raji, CD19+ FL cells Concentration: 0.01 nM, 0.1 nM, and 1 nM Incubation Time: 20 hours Result: Increased the human NK cell cytotoxicity on Daudi, Raji, CD19+ FL cells.

[In Vivo]

Inbakicept (0.2 mg/kg；静脉注射；每周两次，持续 2 周) 在小鼠模型中增强利妥昔单抗对致死性 Daudi 淋巴瘤攻击的保护作用[1]。 Animal Model: SCID mice with Daudi models[1] Dosage: 0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg Administration: Intravenous injection; twice weekly, for 2 weeks Result: Enhanced rituximab-directed control of Raji lymphoma challenge.

[References]

[1]. Rosario M, et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016 Feb 1;22(3):596-608.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.